Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBi
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
11:34am, Tuesday, 07'th Apr 2026
New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX
IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims
10:01am, Tuesday, 07'th Apr 2026
ImmunityBio responds to an FDA warning over misleading Anktiva claims and outlines compliance fixes as strong sales growth and expansion efforts remain in focus.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:01am, Tuesday, 07'th Apr 2026
LOS ANGELES, April 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityB
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
09:00am, Tuesday, 07'th Apr 2026
NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class p
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
01:57am, Tuesday, 07'th Apr 2026
NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March
Why ImmunityBio Stock Slumped on Monday
07:41pm, Monday, 06'th Apr 2026
It sent the company a warning letter about a TV ad and a podcast episode about Anktiva. ImmunityBio sounded a contrite note in response.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
SAN FRANCISCO, April 06, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Immuni
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
07:30am, Monday, 06'th Apr 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Ad
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19,
ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
03:55am, Monday, 06'th Apr 2026
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §�
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
03:49am, Monday, 06'th Apr 2026
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Sunday, 05'th Apr 2026
New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/26/26
